Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
350 Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.